- call +1-201-465-4211
- email sales@mrinsights.biz
Lung cancer is a malignant lung tumor characterized by uncontrolled cell growth in tissues of the lung.
Scope of the Report:
Robust healthcare expenditure within the developed countries, increasing pollution, government initiatives for lung cancer, and rising cases of smoking are some of the major factors that fuel the growth of the market.
The global Lung Cancer Diagnosis and Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Lung Cancer Diagnosis and Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
This report studies the Lung Cancer Diagnosis and Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Lung Cancer Diagnosis and Therapeutics market by product type and applications/end industries.
Market Segment by Companies, this report covers
AstraZeneca
Eli Lilly
Sanofi
ArQule
Daiichi Sankyo
Celgene
Merck
Pfizer
Boehringer Ingelheim
Roche
Genentech
GSK
Pharmacyclics
Novartis
Bayer
Bristol-Myers Squibb
Eisai
AbbVie
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Market Segment by Applications, can be divided into
Hospitals
Cancer Research Centers
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Lung Cancer Diagnosis and Therapeutics Market Overview
1.1 Product Overview and Scope of Lung Cancer Diagnosis and Therapeutics
1.2 Classification of Lung Cancer Diagnosis and Therapeutics by Types
1.2.1 Global Lung Cancer Diagnosis and Therapeutics Revenue Comparison by Types (2017-2023)
1.2.2 Global Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Types in 2017
1.2.3 Non-Small Cell Lung Cancer
1.2.4 Small Cell Lung Cancer
1.3 Global Lung Cancer Diagnosis and Therapeutics Market by Application
1.3.1 Global Lung Cancer Diagnosis and Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Cancer Research Centers
1.4 Global Lung Cancer Diagnosis and Therapeutics Market by Regions
1.4.1 Global Lung Cancer Diagnosis and Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Lung Cancer Diagnosis and Therapeutics Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Lung Cancer Diagnosis and Therapeutics Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Lung Cancer Diagnosis and Therapeutics Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Lung Cancer Diagnosis and Therapeutics Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Lung Cancer Diagnosis and Therapeutics Status and Prospect (2013-2023)
1.5 Global Market Size of Lung Cancer Diagnosis and Therapeutics (2013-2023)
2 Manufacturers Profiles
2.1 AstraZeneca
2.1.1 Business Overview
2.1.2 Lung Cancer Diagnosis and Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 AstraZeneca Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.2 Eli Lilly
2.2.1 Business Overview
2.2.2 Lung Cancer Diagnosis and Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Eli Lilly Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.3 Sanofi
2.3.1 Business Overview
2.3.2 Lung Cancer Diagnosis and Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Sanofi Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.4 ArQule
2.4.1 Business Overview
2.4.2 Lung Cancer Diagnosis and Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 ArQule Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.5 Daiichi Sankyo
2.5.1 Business Overview
2.5.2 Lung Cancer Diagnosis and Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Daiichi Sankyo Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.6 Celgene
2.6.1 Business Overview
2.6.2 Lung Cancer Diagnosis and Therapeutics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Celgene Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.7 Merck
2.7.1 Business Overview
2.7.2 Lung Cancer Diagnosis and Therapeutics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Merck Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.8 Pfizer
2.8.1 Business Overview
2.8.2 Lung Cancer Diagnosis and Therapeutics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Pfizer Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.9 Boehringer Ingelheim
2.9.1 Business Overview
2.9.2 Lung Cancer Diagnosis and Therapeutics Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Boehringer Ingelheim Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.10 Roche
2.10.1 Business Overview
2.10.2 Lung Cancer Diagnosis and Therapeutics Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Roche Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.11 Genentech
2.11.1 Business Overview
2.11.2 Lung Cancer Diagnosis and Therapeutics Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Genentech Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.12 GSK
2.12.1 Business Overview
2.12.2 Lung Cancer Diagnosis and Therapeutics Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 GSK Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.13 Pharmacyclics
2.13.1 Business Overview
2.13.2 Lung Cancer Diagnosis and Therapeutics Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Pharmacyclics Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.14 Novartis
2.14.1 Business Overview
2.14.2 Lung Cancer Diagnosis and Therapeutics Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Novartis Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.15 Bayer
2.15.1 Business Overview
2.15.2 Lung Cancer Diagnosis and Therapeutics Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Bayer Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.16 Bristol-Myers Squibb
2.16.1 Business Overview
2.16.2 Lung Cancer Diagnosis and Therapeutics Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Bristol-Myers Squibb Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.17 Eisai
2.17.1 Business Overview
2.17.2 Lung Cancer Diagnosis and Therapeutics Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Eisai Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.18 AbbVie
2.18.1 Business Overview
2.18.2 Lung Cancer Diagnosis and Therapeutics Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 AbbVie Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
3 Global Lung Cancer Diagnosis and Therapeutics Market Competition, by Players
3.1 Global Lung Cancer Diagnosis and Therapeutics Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Lung Cancer Diagnosis and Therapeutics Players Market Share
3.2.2 Top 10 Lung Cancer Diagnosis and Therapeutics Players Market Share
3.3 Market Competition Trend
4 Global Lung Cancer Diagnosis and Therapeutics Market Size by Regions
4.1 Global Lung Cancer Diagnosis and Therapeutics Revenue and Market Share by Regions
4.2 North America Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
4.3 Europe Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
4.5 South America Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
5 North America Lung Cancer Diagnosis and Therapeutics Revenue by Countries
5.1 North America Lung Cancer Diagnosis and Therapeutics Revenue by Countries (2013-2018)
5.2 USA Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
5.3 Canada Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
5.4 Mexico Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
6 Europe Lung Cancer Diagnosis and Therapeutics Revenue by Countries
6.1 Europe Lung Cancer Diagnosis and Therapeutics Revenue by Countries (2013-2018)
6.2 Germany Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
6.3 UK Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
6.4 France Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
6.5 Russia Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
6.6 Italy Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Lung Cancer Diagnosis and Therapeutics Revenue by Countries
7.1 Asia-Pacific Lung Cancer Diagnosis and Therapeutics Revenue by Countries (2013-2018)
7.2 China Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
7.3 Japan Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
7.4 Korea Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
7.5 India Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
8 South America Lung Cancer Diagnosis and Therapeutics Revenue by Countries
8.1 South America Lung Cancer Diagnosis and Therapeutics Revenue by Countries (2013-2018)
8.2 Brazil Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
8.3 Argentina Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
8.4 Colombia Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Lung Cancer Diagnosis and Therapeutics by Countries
9.1 Middle East and Africa Lung Cancer Diagnosis and Therapeutics Revenue by Countries (2013-2018)
9.2 Saudi Arabia Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
9.3 UAE Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
9.4 Egypt Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
9.5 Nigeria Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
9.6 South Africa Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2013-2018)
10 Global Lung Cancer Diagnosis and Therapeutics Market Segment by Type
10.1 Global Lung Cancer Diagnosis and Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Global Lung Cancer Diagnosis and Therapeutics Market Forecast by Type (2018-2023)
10.3 Non-Small Cell Lung Cancer Revenue Growth Rate (2013-2023)
10.4 Small Cell Lung Cancer Revenue Growth Rate (2013-2023)
11 Global Lung Cancer Diagnosis and Therapeutics Market Segment by Application
11.1 Global Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Application (2013-2018)
11.2 Lung Cancer Diagnosis and Therapeutics Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Cancer Research Centers Revenue Growth (2013-2018)
12 Global Lung Cancer Diagnosis and Therapeutics Market Size Forecast (2018-2023)
12.1 Global Lung Cancer Diagnosis and Therapeutics Market Size Forecast (2018-2023)
12.2 Global Lung Cancer Diagnosis and Therapeutics Market Forecast by Regions (2018-2023)
12.3 North America Lung Cancer Diagnosis and Therapeutics Revenue Market Forecast (2018-2023)
12.4 Europe Lung Cancer Diagnosis and Therapeutics Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Lung Cancer Diagnosis and Therapeutics Revenue Market Forecast (2018-2023)
12.6 South America Lung Cancer Diagnosis and Therapeutics Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Lung Cancer Diagnosis and Therapeutics Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Lung Cancer Diagnosis and Therapeutics Picture
Table Product Specifications of Lung Cancer Diagnosis and Therapeutics
Table Global Lung Cancer Diagnosis and Therapeu
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
